Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCING: Glyburide in Acute Traumatic Spinal Cord Injury
NCT05426681Phase 1Recruiting
- Start
- Jul 2022
- Primary completion
- May 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of glibenclamide in spinal cord injury (SCI). Primary endpoints: Rate of recruitment of patients with tSCI within the specified time window and Number of drug related adverse events at 1 year. Started Jul 2022; status: recruiting.
02
Drugs
glibenclamide
03
Conditions
spinal cord injury (SCI)
Beyond the preview
Go deeper on NCT05426681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05426681.